SCHEMBL737418

SCHEMBL737418

COc1ccc(N2CC3(CCNCC3)OCC2=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 6/20 0.44
OPRM1 P35372 2/20 0.44
HTR3E A5X5Y0 1/20 0.42
HTR3B O95264 1/20 0.42
ADRB1 P08588 1/20 0.42
HTR3A P46098 1/20 0.42
HTR3D Q70Z44 1/20 0.42
HTR3C Q8WXA8 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 3/20 0.41
POLB P06746 2/20 0.41
GAA P10253 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
NPC1 O15118 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL736127 0.86 ADRB1 (0.46) SIGMAR1OPRM1ADRB1MAPTPOLB
SCHEMBL735996 0.85 SIGMAR1 (0.47) SIGMAR1OPRM1ADRB1MAPTRAB9A
SCHEMBL735671 0.84 CHRNB2 (0.46) SIGMAR1OPRM1
SCHEMBL736873 0.83 SIGMAR1 (0.47) SIGMAR1OPRM1ALDH1A1
SCHEMBL737442 0.82 SIGMAR1 (0.62) SIGMAR1OPRM1MEN1KMT2AMAPT
SCHEMBL738043 0.82 GRM5 (0.41) SIGMAR1OPRM1CYP3A4CYP2C19
SCHEMBL736045 0.82 CHRNB2 (0.44) SIGMAR1OPRM1NPC1
SCHEMBL737073 0.82 SIGMAR1 (0.46) SIGMAR1OPRM1POLB
SCHEMBL735135 0.82 SSTR5 (0.46) SIGMAR1HTR3EHTR3BADRB1HTR3A
SCHEMBL735645 0.81 OPRM1 (0.44) SIGMAR1OPRM1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138206-B2 Piperidine derivative MSD. K.K. (JP) 2012-03-20 US disclosed
US-20090137576-A1 Novel Piperidine Derivative MSD K.K. (JP) 2009-05-28 US disclosed
EP-1892241-A1 NOVEL PIPERIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137576-A1 Novel Piperidine Derivative HRH4, HRH3, HRH1 SIGMAR1 11/4885OPRM1 15/4885HTR3E 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.